NEW YORK (GenomeWeb News) — Pharmacogenomics test developer MolecularMD has reeled in $3 million in financing from the Ballast Point Ventures, according to the St. Petersburg, Fla.-based venture capital firm.

MolecularMD is focused on developing molecular diagnostic tests to speed clinical development and regulatory approval of cancer therapies. The company's first tests were associated with imatinib (Gleevec), Novartis' treatment for chronic myelogenous leukemia, and it plans to expand into other cancer areas, including colon and lung cancer.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Cell this week: Leukemia-like disease in soft-shell clams, mNET-seq method for profiling growing transcripts, and more.

While James Watson and Francis Crick are credited for discovering the structure of DNA, Rich proved their theory of a double helix structure was correct when he produced a distinct image of the structure.

Nature News reports that early users of Oxford Nanopore's hand-held MinIon are giddy about the technology and its uses. 

According to MIT Technology Review, Apple is collaborating with researchers to develop apps for consumer DNA testing.